GW raises $87.9m to progress epilepsy drugs
This article was originally published in Scrip
Executive Summary
GW Pharmaceuticals has priced an $87.9m follow-on offering on the Nasdaq Global Market, which the company will use to develop its epilepsy drugs, particularly Phase II-ready Epidiolex (cannabidiol extract).